Company Encyclopedia
View More
name
LAVA Therapeutics NV
LVTX.US
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.
1.875 T
LVTX.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
E
BiotechnologyIndustry
Industry Ranking375/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-101.51%E
    • Profit Margin-464.59%E
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-32.06%E
    • Net Profit YoY16.10%B
    • Total Assets YoY-37.72%E
    • Net Assets YoY-61.56%E
  • Cash ScoreD
    • Cash Flow Margin-21.52%D
    • OCF YoY-32.06%E
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreE
    • Gearing Ratio75.57%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    LAVA Therapeutics Announces Voluntary Delisting from Nasdaq

    LAVA Therapeutics NV announced its voluntary delisting from Nasdaq, with trading suspended on November 21, 2025. Nasdaq filed a Form 25 with the SEC to remove the shares from listing. LAVA plans to terminate its reporting obligations by filing a Form 15 with the SEC around December 1, 2025. This information is for informational purposes only and not financial advice.

    Reuters·
    US
    LVTX
    0.00%
    Reuters·
    US
    LVTX
    0.00%

    LAVA Therapeutics NV Held Extraordinary General Meeting

    LAVA Therapeutics NV held an extraordinary general meeting on November 7, 2025, where shareholders approved the appointment of Owen Hughes as executive director and Thomas Burns, Bradley Sitko, and Maricel Montano as non-executive directors. The meeting also granted discharge to board members for actions prior to the meeting and approved a resolution for a Dutch statutory merger with LAVA Therapeutics New Topco B.V., including the issuance of class A and B shares to shareholders.

    Reuters·
    US
    LVTX
    0.00%
    Reuters·
    US
    LVTX
    0.00%

    LAVA Therapeutics NV | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    LVTX
    0.00%
    LB filings·
    US
    LVTX
    0.00%

    Cooperatieve Gilde Healthcare IV U.A. Reports Disposal of Common Shares of LAVA Therapeutics NV

    Cooperatieve Gilde Healthcare IV U.A. has reported the disposal of common shares of LAVA Therapeutics NV. The Form 4 filing was submitted by multiple reporting persons, including Cooperatieve Gilde Healthcare IV U.A. The full filing is accessible via the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice.

    Reuters·
    US
    LVTX
    0.00%
    Reuters·
    US
    LVTX
    0.00%

    Cooperatieve Gilde Healthcare IV U.A. Reports Disposal of Common Shares in LAVA Therapeutics NV

    Cooperatieve Gilde Healthcare IV U.A., a 10% beneficial owner, has reported the disposal of common shares in LAVA Therapeutics NV (LVTX). The Form 4 was filed by multiple reporting persons, including Cooperatieve Gilde Healthcare IV U.A. The full filing is accessible via the provided link. This news brief was generated by Public Technologies (PUBT) and is for informational purposes only, not to be considered as financial, investment, or legal advice.

    Reuters·
    US
    LVTX
    0.00%
    Reuters·
    US
    LVTX
    0.00%